HoLVP

Holmium Laser Vaporization of the Prostate (HoLVP) is a safe and effective BPH treatment option that provides immediate symptom relief with few complications6.

The holmium laser penetrates just enough to precisely and quickly vaporize tissue without causing deeper thermal injury, coagulation necrosis or collateral damage7.

HoLVP is a virtually bloodless, out-patient procedure that offers quick recovery time and a rapid return to normal activity7.

HoLVP Is Durable At 7 Years

  • Durable outcomes over 7 years1
  • 47% decrease in AUA symptom score
  • 83% improvement in flow rate
  • 15% reoperation rate comparable to TURP

HoLVP Results Are Comparable to TURP

  • HoLVP and TURP outcomes equivalent at 12 months
  • Catheterization times for HoLVP shorter than TURP2
  • Hospital stay for HoLVP shorter than TURP
  • No post-operative irrigation required with HoLVP
  • No initial dysuria

High Power Holmium Ideal for BPH

The holmium laser penetrates just enough to precisely and quickly vaporize tissue without causing deeper thermal injury, coagulation necrosis or collateral damage

Videos

Lumenis Urology Devices

MOSES PulseTM 120H

All-in-one urology platform for Vaporization, HoLEP, Flexible Ureteroscopic Lithotripsy and PCNL.

Lumenis® Pulse™30H

High Performance Fragmentation with User Experience in Mind.

VersaPulse® PowerSuiteTM 80/100W

A powerful combination of Holmium and Nd:YAG wavelengths for short or long duration procedures.

Holmium Accessories

Performance, Durability
and Reliability

References

  1. Tan A, et al. Long-term Results of High-power Holmium Laser Vaporization (Ablation) of the Prostate., BJU International, 92:707-9, 2003
  2. Mottet N, et al. Randomized Comparison of Transurethral Electroresection of Holmium:YAG Laser Vaporization for Symptomatic Benign Hyperplaysia. J Endo, 13:127-120, Mar 1999
  3. Kruntz RM. Current Role of Lasers in the Treatment of Benign Prostatic Hyperplasia. Eur Urol, 49:961-969, Jun 2006
  4. Gilling, et al. Use of Holmium Laser in the Treatment of Benign Prostatic Hyperplasia. J Endo, 10(5):459-461, Oct 1996
  5. The Canadian Journal of Urology, Oct 2007, Dr. Derek Matoka & Dr. Timothy Averch
  6. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH), 2010
  7. Tholomier C, Valdivieso R, Hueber P-A, Zorm KC. Photoselective laser ablation of the prostate: a review of the current 2015 tissue ablation options. Can J Urol 2015;22(Suppl 1):45-52

PB-2007840 rev A